Skip to content

Remote-by-Default Care in the COVID-19 Pandemic

Remote-by-Default Care in the COVID-19 Pandemic: Addressing the Micro-, Meso-, and Macro-level Challenges of a Radical New Service Model

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04435041
Enrollment
103
Registered
2020-06-17
Start date
2020-05-13
Completion date
2022-02-28
Last updated
2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

18 month study, funded by ESRC COVID-19 research fund. The aim is to explore and support the rapid shift from face-to-face to remote (telephone and video) conversations in primary care. There are three components: a study of clinical interactions and decision making (micro); four locality-based organisational case studies of new models of care (meso); abd a a study of how digital innovation can support NHS infrastructure and vice versa (macro).

Detailed description

18 month study, funded by ESRC COVID-19 research fund. The aim is to explore and support the rapid shift from face-to-face to remote (telephone and video) conversations in primary care. There are three components: a study of clinical interactions and decision making (micro); four locality-based organisational case studies of new models of care (meso); abd a a study of how digital innovation can support NHS infrastructure and vice versa (macro). The methods are mainly qualitative (interviews, virtual ethnography, analysis of documents, micro-analysis of conversations) and are designed to inform action research. Key deliverables: At least two evidence-based assessment tools: qualitative (questions for remote assessment of breathlessness) and quantitative (a COVID-19-specific early warning score) Transferable lessons about how to achieve rapid spread and scale-up, spread in real time through our extensive intersectoral networks Strengthened infrastructure for supporting digital innovation in the NHS

Interventions

None listed

Sponsors

University of Plymouth
CollaboratorOTHER
Nuffield Trust
CollaboratorUNKNOWN
University of Oxford
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inclusion criteria for interviews Willing and able to give informed consent for participation Aged 18 years or above Staff involved in delivering remote-by-default services in the frontline or 'back offices' Patients/carers who have crossed paths with primary care services during the Covid pandemic. Pharmacy case studies: Staff involved in delivering remote pharmacist consultation services in the frontline or 'back offices' Patients/carers who have crossed paths with community pharmacy primary care services during the COVID-19 pandemic. Inclusion criteria for video and telephone consultations Patients who have remote primary care consultation regarding symptoms associated with COVID-19 and their clinicians (based in Oxford/Thames Valley) who have agreed to participate in the study Inclusion criteria for focus groups Patients that have experienced self-reported 'long Covid' symptoms (for patient only focus groups) Clinicians that have experienced self-reported 'long Covid' symptoms (for clinician only focus groups)

Exclusion criteria

Patients or clinicians who are too ill to be interviewed \-

Design outcomes

Primary

MeasureTime frameDescription
Remote COVID-19 Assessment in Primary Care (RECAP) Early warning score18 monthsA set of questions and a predictive tool built into electronic records, designed to distinguish people with suspected covid-19 who need to go to hospital from those who can safely be monitored at home. The final Remote COVID-19 Assessment in Primary Care (RECAP) Early warning score score divides people into 'green' (stay at home, self-monitor), amber (professional monitoring e.g., via virtual wards with home oximetry), or red (assess in person promptly).

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026